(lp0
S'The TrovaGene, Inc.  Receives $6.75 Average Target Price from Analysts Petro Global News 24 - Jan 31, 2017 Shares of TrovaGene, Inc.  have received an average recommendation of Hold from the nine research firms that are covering the company.'
p1
aS'Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical ... PR Newswire  - Apr 13, 2017 SAN DIEGO, April 13, 2017 /PRNewswire/ -- Trovagene, Inc. , a precision medicine biotechnology company, announced today that Dr.'
p2
aS'Trovagene Announces Broadening Network of Commercial Distributors PR Newswire  - Jan 12, 2017 SAN DIEGO, Jan. 12, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  technologies, today announced that it has signed agreements with seven strategic partners across Europe and the Middle East for&nbsp;...'
p3
aS'Trovagene to Announce Fourth Quarter and Year End 2016 Financial Results and ... PR Newswire  - Mar 1, 2017 SAN DIEGO, March 1, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, announced today that it will report financial results for the fourth quarter and year ended December 31, 2016&nbsp;...'
p4
aS"Trovagene to Present at The MicroCap Conference on April 4, 2017 in New York City PR Newswire  - Mar 27, 2017 SAN DIEGO, March 27, 2017 /PRNewswire/ -- Trovagene, Inc. , a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch, will be presenting at this year's MicroCap Conference on April 4,&nbsp;..."
p5
aS'Trovagene Reports Fourth Quarter and Year End 2016 Financial Results PR Newswire  - Mar 15, 2017 SAN DIEGO, March 15, 2017 /PRNewswire/ -- Trovagene, Inc. , a precision medicine biotechnology company today reported financial results for the fourth quarter and year ended December 31, 2016.Why TrovaGene Inc  Reported Restructuring Plan? - StockNewsUnionTrovagene nabs rights to leukemia candidate from Nerviano Medical - Seeking Alpha'
p6
aS"Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments PR Newswire  - Nov 9, 2016 SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, today reported its financial results and accomplishments for the third quarter ended September 30, 2016.TrovaGene's  CEO Bill Welch on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha"
p7
aS'Trovagene announces a reorganization to accelerate global distribution of ... PR Newswire  - Dec 13, 2016 SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, announced today that it will increase its focus on the global distribution of kits and systems to clinical&nbsp;...Trovagene to Focus More on Liquid Biopsy Testing Market - Yahoo FinanceTrovagene Axes 20 Staffers, Refocuses on Distributing Kits, Systems - Genetic Engineering & Biotechnology News'
p8
aS'Earnings Reaction History: TrovaGene, Inc., 75.0% Follow-Through Indicator, 7 ... Nasdaq - Mar 15, 2017 TrovaGene, Inc.  is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement.'
p9
aS'What are the Levels Indicating for This Stock: Trovagene Inc.  Rives Journal - 17 hours ago In terms of moving averages for Trovagene Inc. , the 200-day is currently at 1.19, the 50-day is 0.22, and the 7-day is resting at 0.13.'
p10
a.